CClinicalTrials.gg
CompletedNCT02560155DECO-SSIUpdated Feb 27, 2018

Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial

An interventional study of Mupirocin 2% nasal ointement and Chlorhexidine sol 4% in Orthopedic Disorders and Surgical Site Infection, sponsored by Lindenhofgruppe AG. Completed at 1 site in Switzerland. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-02-27.

Sponsored by Lindenhofgruppe AG · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
1,300
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Surgical site infections are a major postoperative complication and are mostly due to colonization with endogenous germs, like Staphylococcus aureus, Staphylococcus epidermidis or Propionibacterium acnes. In literature, preoperative decolonization procedures showed a trend in lowering surgical site infection rates, but especially in orthopedic surgery data is controversial and randomized controlled trials are lacking. In the main study, the study investigators aim at performing a controlled prospective randomized interventional trial to measure the impact of preoperative decolonization of nasal Staphylococcus aureus carriers on surgical site infection rates in orthopedic surgery. In an alongside study a controlled prospective randomized interventional trial to measure the impact of preoperative skin decolonization of patients undergoing an orthopedic procedure will be conducted.

Read the detailed description

All participants will be assessed for eligibility during preoperative othopedic consultation. 2-3 weeks prior operation date participants will be screened for Staph. aureus carriage by nose-swab. According to nose-swab results randomizaton and allocation to study arm will be performed.

After one and three months post-operatively participants will be asked by phone interview if surgical site infections occured. Results have to be confirmed by orthopedic surgeon if possible.

02

Conditions studied

  • Orthopedic Disorders
  • Surgical Site Infection

Keywords

  • Orthopedic surgery
  • Surgical site infection
  • Decolonization
  • Staphylococcus aureus
03

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patient older than 16 years
  • patient undergoing elective orthopedic procedure at the Sonnenhof hospital
  • decolozination protocol can be performed timely
  • signed informed consent

Exclusion criteria

Exclusion Criteria:

  • no orthopedic surgery planned
  • allergy to mupirocin or chlorhexidine
  • presence of a nasal foreign body
  • no informed consent
  • pregnancy
  • decolozination protocol can't be followed timely
  • patients undergoing treatment/surgery for a documented infection
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,300 participants (actual)

Study arms

  • No intervention
    Nose-SA-carriers control

    Control Group, no intervention

  • Active comparator
    Nose-SA-carriers decolonized

    Chlorhexidine sol 4%; Mupirocin 2% nasal ointement 1 shower/day for 5 days and Nasal ointement 2x/d in each nostril for 5 days preoperatively

    Drug: Mupirocin 2% nasal ointement · Drug: Chlorhexidine sol 4%

  • No intervention
    Non-nose-SA-carriers control

    Control Group, no intervention

  • Active comparator
    Non-nose-carriers decolonized

    Chlorhexidine sol 4% shower, daily for 5 days preoperatively

    Drug: Chlorhexidine sol 4%

Interventions

  • DrugMupirocin 2% nasal ointement

    Mupirocin nasal ointement 2x/d for 5 days preoperatively

    Also known as: Bactroban Nasal

  • DrugChlorhexidine sol 4%

    Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively

    Also known as: Lifo-Scrub sol 4%

05

What researchers measure

Primary outcomes

  1. Overall number of participants with surgical site infections 3 months postoperatively

    Phone interview and orthopedic assessement

    Time frame: 3 months

Secondary outcomes

  1. Number of participants with surgical site infections at 1 and 3 months postoperatively

    Phone interview and orthopedic assessement

    Time frame: 1 and 3 months

Other outcomes

  1. Total screening costs

    Total screening costs divided by the number of prevented SSI to assess cost-effectiveness

    Time frame: one year

06

Study locations

1 site
  • Sonnenhofspital, Lindenhofgruppe
    Bern, 3006, Switzerland
07

Registry details

Key details

Study ID
NCT02560155
Lead sponsor
Lindenhofgruppe AG
Collaborators
Clinical Trials Unit Bern (CTU), Lindenhofstiftung, Labormedizinisches Zentrum Dr. Risch
Responsible party
Sponsor
First posted
Sep 25, 2015
Start date
Nov 2015
Primary completion
Oct 2017
Completion
Feb 2018
Last update
Feb 27, 2018

Study contacts

Jan Brügger, Dr. med.
principal investigator · Lindenhofgruppe AG

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion